pomalidomide / Generic mfg. - LARVOL DELTA

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations (ASH 2025) - P | "The CR1-MRD⁻ group exhibited a trend toward superior median RFS compared to the combined CR1-MRD⁺ and R/R group (not reached vs. 404 days [95% CI: 30-777 days], P=0.073).In terms of post-CAR-T management, 20 patients received combination therapy (including three patients received tyrosine kinase inhibitors, one patients received zanubrutinib, two patients received pomalidomide, three patients received venetoclax, one patients received blinatumomab, one patients received inotuzumab ozogamicin, and four patients received allo-HSCT), while 21 patients underwent observation only. Front-line consolidation with CAR-T during CR1-MRD⁻ in patients with high-risk molecular alterations may yield better RFS outcomes compared to treatment administered in R/R or MRD⁺ settings. No RFS benefit from post-CAR-T combination therapy was observed in this cohort, highlighting the need for validation with longer follow-up durations and larger patient cohorts."

Clinical • IO biomarker • Real-world • Real-world effectiveness • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • IKZF1 • KMT2A • TP53

Trial in progress: Phase I trial to evaluate safety of oral azacytidine in combination with pomalidomide as maintenance therapy in AML (ASH 2025) - "Oral azacitidine has demonstrated improved relapse-free and overall survival in older, transplant-ineligible patients, establishing a role in AML maintenance (Hunault-Berger M Blood Cancer J. 2017). In resource-limited settings, delivery of high-dose cytarabine or allogeneic transplant is frequently compromised due to multidrug-resistant infections, poor performance status (PS), and lack of donors...Participants must have adequate hematologic recovery, ECOG PS 0–2, with no prior exposure to azacytidine or venetoclax...Participants are enrolled sequentially into each cohort to ensure safety. Dose escalation is ongoing as per protocol."

Clinical • Combination therapy • P1 data • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Heart Failure • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Liver Failure • Nephrology • Renal Disease • CRBN • IKZF1 • IKZF3

Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies (ASH 2025) - P1/2 | "This Phase I/II study (Study CCS1477-02) of Ino with pomalidomide and dexamethasone (InoPd) showed high response rates (75% ORR) with a manageable safety profile in heavily pre-treated relapsed/refractory multiple myeloma (RRMM), all of which were refractory to their last line of therapy. Serial blood and bone marrow samples are being collected for exploratory biomarker analysis to understand mechanisms of response to treatment or disease progression. These cohorts will be opened in approximately 8 sites in the UK and US."

Clinical • Combination therapy • IO biomarker • Metastases • P1/2 data • Hematological Malignancies • Multiple Myeloma • Myelodysplastic Syndrome • Oncology • IRF4

Ixazomib combined with daratumumab-based regimens as first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma: A real-world historical database analysis from China (ASH 2025) - P2 | "The DI-based regimens included DICd (C: cyclophosphamide; d: dexamethasone) plus vinorelbine (VDS), DId plus VDS, DId plus denosumab, DId plus venetoclax (VEN), DIPd (P: pomalidomide), DIR (R: lenalidomide), and DIRd plus VEN. Conclusion The DI-based regimen, as an initial treatment option for transplant-ineligible NDMM patients, demonstrates efficacy comparable to that observed in previous prospective randomized controlled trials (RCTs) (NCT03012880, NTR6297, ORR: 71–96%). This real-world study conducted in China further supports the promising efficacy and acceptable safety profile of the ixazomib plus daratumumab-based regimen as a first-line treatment for transplant-ineligible NDMM patients in routine clinical practice, including among elderly patients with multiple comorbidities."

Clinical • Real-world • Real-world evidence • Cardiovascular • CNS Disorders • Diabetes • Hematological Disorders • Hematological Malignancies • Hepatology • Hypertension • Metabolic Disorders • Multiple Myeloma • Nephrology • Renal Disease • Transplantation • Vascular Neurology

Administration- and adverse event-related costs among patients with multiple myeloma treated with B-cell maturation antigen (BCMA)-targeted agents (ASH 2025) - " A 3-year BIM was developed to evaluate administration and AE-related costs for patients with RRMM and ≥1 prior line of therapy who had received belamaf plus bortezomib and dexamethasone (BVd), belamaf plus pomalidomide and dexamethasone (BPd), cilta-cel, ide-cel, or teclistamab. BVd/BPd had substantially lower administration and AE-related costs vs CAR-T and bispecific therapies, which have high costs mostly due to hospitalizations, premedication, and CRS rates."

Adverse events • Clinical • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Comprehensive cost analysis of 4th line + therapies for relapsed/refractory multiple myeloma in Germany: Drug, co-medication, and office-based treatment perspective (ASH 2025) - "Whilst there is no official myeloma registry in Germany, treatments we considered were reimbursable combination therapies frequently used in the 4 th line treatment of RRMM in Germany in 2023, containing: carfilzomib, daratumumab, elotuzumab, melflufen, selinexor, talquetamab and teclistamab, and newly approved therapeutic options like elranatamab, along with evidence-based recommendations regarding premedication, comedication, and mandatory prophylaxis of treatment-related adverse events, as outlined in the Summary of Product Characteristics (SmPC) and published literature... Costs for myeloma drugs and combinations show a broad variation, from 88.863€ for Elotuzumab/Revlimid/Dexamethasone (ERd), to 178.850€ for talquetamab treatment. The second lowest in terms of annual costs was melflufen with 106.839€, followed by Elotuzumab/Pomalidomide/Dexamethasone (EPd):119.301€, teclistamab: 124.626€, Selinexor/Dexamethasone (Sd): 129.976€, elranatamab: 146.706€ and..."

Cost-analysis • HEOR • Hematological Malignancies • Multiple Myeloma

High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma. (ASH 2025) - "Case Report We present the case of a female patient diagnosed with IgG multiple myeloma in 2015, initially treated with induction chemotherapy using lenalidomide, bortezomib, and dexamethasone (RVD), followed by autologous HSCT...She subsequently progressed on a combination of daratumumab, lenalidomide, and dexamethasone. Further disease progression occurred on a regimen of ixazomib, pomalidomide, and dexamethasone. She then achieved a temporary response to carfilzomib, lenalidomide, and dexamethasone, followed by a second autologous HSCT, but relapsed again after approximately one year of maintenance therapy...While this association warrants further investigation, it emphasizes the need for ongoing observation of patients who have received CAR T-cell therapy. Future studies should aim to clarify the potential mechanistic links, including clonal evolution, selective pressures imposed by immunotherapy, and the contribution of prior cytotoxic exposures."

IO biomarker • Acute Lymphocytic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Cardiomyopathy • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • TP53

Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study (ASH 2025) - "Novel BCMA-targeted therapies, such as CAR T-cells (cilta-cel from 2nd line, ide-cel from 3rd line) and bispecific T-cell engagers (e.g., teclistamab, elranatamab from 4th line), have become new standards of care...Abbreviations: K=carfilzomib; E=elotuzumab; Pom=pomalidomide; d=dexamethasone; Isa=isatuximab; F=panobinostat; R=lenalidomide; Tec=teclistamab; X=selinexor; Elra=elranatamab; Belamaf=belantamab mafodotin; Ixa=ixazomib... This real-world study of 100 MM patients relapsing after anti-BCMA CAR T-cell treatment shows that 91% were in their 4th or 5th line of therapy. A large majority were triple-class exposed, and 52% were lenalidomide-refractory. In the absence of a clear standard of care, common treatments were identified: elotuzumab- and isatuximab-based regimens in the 3rd line; teclistamab and elotuzumab-based options in the 4th line; and teclistamab, elranatamab, and belantamab mafodotin in the 5th line."

CAR T-Cell Therapy • Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Diabetes • Dyslipidemia • Hematological Malignancies • Hypertension • Metabolic Disorders • Multiple Myeloma • Renal Disease

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment exposure patterns indicated a heavily pretreated, triple-class refractory population: proteasome inhibitors (bortezomib 61%, carfilzomib 47%), IMiDs (lenalidomide 67%, pomalidomide 69%), and anti-CD38 monoclonal antibodies (daratumumab 67%). Additional therapies included CAR T-cell therapy (8%), autologous stem cell transplant (23%), Belantamab mafodotin (8%), Talquetamab (10%), and Teclistamab (8%)...Tocilizumab was used in 21% of patients... In comparison to the MagnetisMM-3 trial, this real-world analysis confirms the manageable immune toxicity profile of ELRA, with similarly low rates of grade ≥3 CRS and ICANS. However, the higher 6-month mortality (22.6%) observed in this cohort may reflect broader patient inclusion, including those with significant comorbidities and prior BCMA-directed therapies. Hematologic and infectious toxicities were substantial, reinforcing the need for enhanced monitoring and supportive care strategies in routine clinical use."

Real-world • Real-world evidence • Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Leukemia • Multiple Myeloma • Nephrology • Neutropenia • Plasma Cell Leukemia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment patterns reflected a triple-class refractory population, with high prior exposure to proteasome inhibitors (bortezomib 52%, carfilzomib 48%), IMiDs (lenalidomide 66%, pomalidomide 63%), and anti-CD38 antibodies (daratumumab 51%). Additionally, 35% had received CAR T-cell therapy, 39% underwent ASCT, 24% were treated with Teclistamab, and extramedullary disease and plasma cell leukemia were reported in 11% and 13% of patients, respectively...Grade ≥3 CRS and ICANS occurred in <10 patients each (2.4%), and 24% received tocilizumab for CRS... In this large, real-world cohort, Talquetamab demonstrated favorable short-term survival and a manageable safety profile, consistent with clinical trial data. The higher mortality observed may reflect the heavily pretreated, triple-class refractory population with advanced disease features and comorbidities often seen in real-world settings. Hematologic toxicities remained significant, while lower observed rates of..."

Real-world • Real-world evidence • Retrospective data • Dermatology • Multiple Myeloma • Neutropenia • Plasma Cell Leukemia • Thrombocytopenia

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients (ASH 2025) - "Treatment regimens included selinexor (40–60 mg/week) combined with the KPD regimen (carfilzomib, pomalidomide, dexamethasone) in 6/18 (33.3%) patients; other combinations comprised cytotoxic drugs, aponermin, daratumumab, and venetoclax. Selinexor-based regimens demonstrate clinically meaningful efficacy (ORR 66.7%, median PFS 10.9 months) and a manageable safety profile in heavily pretreated TCE/TCR RRMM patients. These findings support its use as a viable salvage therapy. Further validation through larger prospective trials is warranted to confirm these results."

Clinical • Real-world • Real-world evidence • Multiple Myeloma • Nephrology • Neutropenia • Plasma Cell Leukemia • Plasmacytoma • Renal Disease • Thrombocytopenia • XPO1

Real-world safety and efficacy of aponermin and selinexor-based regimens in patients with multiple myeloma (ASH 2025) - "Treatment regimens predominantly consisted of Apo+selinexor+dexamethasone (65.38%), with other combinations including Apo + daratumumab + selinexor + dexamethasone (11.54%), Apo + selinexor + carfilzomib + pomalidomide + dexamethasone (7.69%), Apo + selinexor + pomalidomide + dexamethasone (7.69%), Apo + selinexor + carfilzomib + dexamethasone (3.85%) and Apo + selinexor + cyclophosphamide + dexamethasone (3.85%). The median age was 66 years (range 29-82), with 65.38% male patients. R-ISS staging showed 11.54% stage I, 42.31% stage II, and 30.77% stage III. High-risk cytogenetic abnormalities included 1q21 gain/amplification (50.00%), t(4; 14) (19.23%), 17p deletion (15.38%) and double-hit HRCA (26.92%)."

Clinical • Real-world • Real-world evidence • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Lymphoma • Multiple Myeloma • Thrombocytopenia

Dermatologic toxicities associated with talquetamab in patients with Relapsed/Refractory multiple myeloma: A systematic review and meta-analysis (ASH 2025) - "Of these, 3 studies (n=194 patients) utilized combination therapy (talquetamab with daratumumab, teclistamab, or pomalidomide), while 5 studies (n=622 patients) administered talquetamab as a monotherapy. The frequency of skin toxicities did not differ significantly between monotherapy and combination therapies. The limited reporting on the grading of skin toxicities highlights the need for further research to more comprehensively define the spectrum of talquetamab-associated adverse events in a clinical setting."

Retrospective data • Review • Dermatology • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Efficacy and safety of aponermin combined with immunomodulators in relapsed/refractory multiple myeloma (ASH 2025) - "Treatment regimens included aponermin plus carfilzomib, thalidomide, and dexamethasone (Apo-KTd); aponermin plus carfilzomib, pomalidomide, and dexamethasone (Apo-KPd); aponermin plus pomalidomide and dexamethasone (Apo-Pd); aponermin plus thalidomide and dexamethasone (Apo-Td), and other combination therapies based on aponermin. Conclusion Aponermin combined with immunomodulators demonstrates good tolerability and definite efficacy for RRMM, especially for long-term treatment. Patients with high-risk cytogenetics, extramedullary lesions, and those who have failed multiple lines of treatment can still benefit."

Clinical • Immunomodulating • IO biomarker • Hematological Malignancies • Multiple Myeloma

Once-weekly carfilzomib (56 mg/m²), pomalidomide, and dexamethasone (K56Pd) in patients with first-relapsed multiple myeloma: a Multicenter, prospective, Real-world evidence from China (ASH 2025) - "Prior therapies included bortezomib (19.4% refractory), lenalidomide (90.3% refractory), and anti-CD38 antibodies (3.2% refractory); 6 (19.4%) were dual-refractory to bortezomib/lenalidomide, and 1 (3.2%) triple-refractory (bortezomib/lenalidomide/anti-CD38). The weekly K56Pd regimen demonstrated meaningful clinical benefits and manageable safety in patients with MM at first relapse in real-world settings."

Clinical • HEOR • Real-world • Real-world evidence • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Leukemia • Leukopenia • Lymphoma • Multiple Myeloma • Thrombocytopenia

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis (ASH 2025) - P3 | " In the len-exposed population, the PFS network comprised 8 RCTs (including DREAMM-8) with comparator regimens: carfilzomib + dexamethasone (Kd), Kd + daratumumab (DKd), isatuximab + carfilzomib + dexamethasone (IsaKd), bortezomib + dexamethasone (Vd), DVd, PVd, and selinexor + Vd (SVd). In the absence of head-to-head randomized controlled trials, these ITC data suggested a high probability that PFS consistently favored BPd vs comparator regimens of interest in len-exposed patients with RRMM, with consistent findings in the IPTW analysis reducing uncertainty in the base-case NMA findings."

Retrospective data • Hematological Malignancies • Multiple Myeloma

Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (ASH 2025) - "Safety profile of POM+LD-DXM was associated to a higher rate of AEs, as expected for a combination. In conclusion, P+LD-DXM can be considered an alternative therapeutic option in r/r MM as this comparison in terms of OS shows that P+LD-DXM is non-inferior to POM+LD-DXM with an advantageous safety profile in terms of hematological and infection events."

Clinical • Combination therapy • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Musculoskeletal Pain • Neutropenia • Thrombocytopenia

Outcomes of venous thromboembolism in multiple myeloma: A nationwide analysis of anticoagulation strategies (ASH 2025) - "The current guideline from ASH has a conditional recommendation regarding the use of anticoagulation for VTE prophylaxis in ambulatory patients with MM receiving lenalidomide-, thalidomide-, or pomalidomide-based regimens. Conclusion MM patients who developed VTE without any prophylactic antithrombotic therapy experienced worse outcomes, including longer hospitalizations, higher healthcare costs, and increased mortality. Use of aspirin or anticoagulants was associated with improved clinical outcomes, underscoring the importance of reinforcing thromboprophylaxis in MM patients."

Cardiovascular • Hematological Malignancies • Multiple Myeloma • Venous Thromboembolism

A real-world study on first-line early switch to kpd regimen in the treatment of multiple myeloma patients with suboptimal induction efficacy or intolerance (ASH 2025) - " Patients from 12medical centers in Henan Province who did not achieve very good partial response (VGPR) after two cycles of first-line induction therapy (VRD [bortezomib + lenalidomide + dexamethasone], VD [bortezomib + dexamethasone], or VPD [bortezomib + pomalidomide + dexamethasone]) or experienced grade ≥2 adverse events (CTCAE criteria) were switched to the KPD regimen(Carfilzomib [20/27 mg/m² on days 1, 2, 8, 9, 15, and 16], pomalidomide [4 mg on days 1-21] and dexamethasone [20 mg on days 1, 2, 8, 9, 15, and 16]). This multicenter real-world observational study suggests that multiple myeloma patients with suboptimal efficacy or intolerance to first-line induction therapy who switch to the KPd regimen early have a high response rate and achieve deeper remission. No new adverse events were observed compared with clinical studies."

Clinical • Real-world • Real-world evidence • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • CD34

Impact of pomalidomide-containing induction chemotherapy on hematopoietic stem cell mobilization in multiple myeloma: A retrospective cohort study (ASH 2025) - "Preclinical data suggest POM upregulates CXCR4 on hematopoietic stem cells (HSCs), potentially impairing mobilization, similar to lenalidomide (LEN)...Mobilization used G-CSF ± plerixafor ± high-dose cyclophosphamide (HD-CTX)...Daratumumab exposure significantly impairs mobilization efficiency. Older age, prolonged induction, and multi-agent regimens negatively impact stem cell harvest. These findings support routine use of HD-CTX or plerixafor for POM-exposed patients and highlight the need for risk-adapted mobilization strategies in TE-NDMM."

Retrospective data • Hematological Malignancies • Multiple Myeloma • CD34 • CXCR4

Real-world stratified treatment strategies in transplant-eligible newly diagnosed multiple myeloma: A multicohort study (ASH 2025) - "Methods Real-world cohorts from First Affiliated Hospital of Sun Yat-sen University (2024–2025): - UHiR cohort (n=26): Dara-KAD (daratumumab, carfilzomib, liposomal doxorubicin, dexamethasone) induction → tandem ASCT → carfilzomib/pomalidomide maintenance. Mobilization remained feasible across all cohorts with proactive plerixafor use. Real-world evidence supports risk-adapted induction, transplantation, and mobilization strategies."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Transplantation • CD34

Aponermin-based regimen as bridging therapy prior to CAR-T cell therapy for relapsed/refractory multiple myeloma (ASH 2025) - "He received induction therapy with the PAD regimen (bortezomib, liposomal doxorubicin, dexamethasone) and DKd regimen (daratumumab, carfilzomib, dexamethasone), achieving a Very Good Partial Response (VGPR)...Maintenance therapy with the KP regimen (carfilzomib, pomalidomide) was administered, during which surveillance studies showed minimal residual disease (MRD) negativity by bone marrow flow cytometry and negative serum and urine immunofixation electrophoresis...Bridging therapy was initiated the following day (February 23, 2025) with Aponermin (10mg/kg on Days 1-5), Selinexor (40mg once weekly), and dexamethasone (20mg once weekly)...The regimen did not adversely impact hematologic recovery following CAR-T cell infusion, and cytokine release syndrome (CRS) was mild and manageable. For patients with triple-class refractory (TCR) or penta-drug refractory multiple myeloma undergoing CAR-T cell therapy, Aponermin-based regimen represents a viable and well-tolerated..."

CAR T-Cell Therapy • Bone Marrow Transplantation • Hematological Malignancies • Inflammation • Multiple Myeloma

Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study. (ASH 2025) - "All patients had been exposed to IMiDs (lenalidomide, pomalidomide, thalidomide), 89% to proteasome inhibitors (bortezomib, carfilzomib, ixazomib), and 64% to anti-CD38 monoclonal antibodies (daratumumab, isatuximab). Initial weekly dosing of K followed by spacing out infusions in responding patients led to better tolerance. Currently, K-based combinations also represent interesting options as bridging therapy to CAR T-cells therapies."

Real-world • Real-world evidence • Retrospective data • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Gastrointestinal Disorder • Heart Failure • Hematological Malignancies • Hypertension • Multiple Myeloma

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting (ASH 2025) - "Among them, six received idecabtagene vicleucel and two received ciltacabtagene autoleucel...Two patients received pomalidomide monotherapy, and six received an elotuzumab-based combination regimen with either pomalidomide or lenalidomide, with or without dexamethasone, as maintenance therapy... Maintenance therapy following CAR T-cell infusion was associated with deepening of response in a subset of our patients (50%) with RRMM. However, the high incidence of infectious complications and hematologic toxicity highlights the need for careful patient selection and monitoring. These preliminary findings suggest that while maintenance may enhance disease control post–CAR T-cell therapy, the risk-benefit balance remains a critical consideration, and infectious complications are a particular concern."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Infectious Disease • Multiple Myeloma • Neutropenia • Respiratory Diseases • Targeted Protein Degradation • CRBN

Successful melphalan flufenamide (melflufen) therapy in patients with severe renal insufficiency (ASH 2025) - "Before melflufen, the patient received 5 prior therapies all of which were discontinued due to different reasons: VMP (10 mo) – progredient disease (PD), Rd (3 mo) – drug exanthema, Vd (7 mo) - PD, DaraKd (10 mo) – heart insufficiency, and DaraPd (4 mo) which was adjusted to daratumumab monotherapy due to side effects on pomalidomide...In total, 9 different prior therapies were administered and discontinued before the use of melflufen: thalidomide/doxorubicine/dexamethasone (12 mo) with thalidomide as a maintenance therapy (2 y) – PD, Vd (12 mo) – polyneuropathy, bendamustine/prednisolone (5 mo) - PD, KRd (4 mo) – VGPR, discontinuation due to patient's request, EloRd (9 mo) – VGPR, DaraRd (2 y) and daratumumab monotherapy (4 mo) - PD, IsaPomd (5 mo) – PD, and liposomal doxorubicine/bortezomib (2 mo)... Both clinical cases showed that melphalan flufenamide (melflufen) can be administered in a reduced dose of e.g. 20 mg and is a highly effective and well-tolerated..."

Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hematological Malignancies • Infectious Disease • Metabolic Disorders • Multiple Myeloma • Musculoskeletal Diseases • Nephrology • Orthopedics • Pulmonary Arterial Hypertension • Renal Disease • Type 2 Diabetes Mellitus • B2M